Leadership & Pay ·
On July 21, 2026, Outlook Therapeutics, Inc. announced stock option grants to CEO Robert C. Jahr (100,000 options) and…
OTLKOutlook Therapeutics, Inc.
On July 21, 2026, Outlook Therapeutics, Inc. announced stock option grants to CEO Robert C. Jahr (100,000 options) and CFO Lawrence A. Kenyon (210,078 options) with an exercise price of $1.4304 per share. The awards vest on July 21, 2027. Additionally, the Compensation Committee approved performance-based cash bonuses of $420,000 for Mr. Jahr and $200,000 for Mr. Kenyon, contingent upon FDA approval of the ONS-5010 (bevacizumab-vikg) Biologics License Application by July 31, 2026. Outlook Therapeutics, Inc. is a biotechnology company developing biologics therapies.